This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Sodium fluoride mouthwash

Updated 2 Feb 2023 | Fluoride

Presentation

Mouthwash solution containing sodium fluoride

Drugs List

  • ENDEKAY FLUORIDE DAILY 0.05% mouthwash
  • FLUORIGARD DAILY 0.05% mouthwash
  • FLUORIGARD FLUORIDE 0.05% oral rinse alcohol-free
  • sodium fluoride 0.05% mouthwash sugar-free
  • Therapeutic Indications

    Uses

    Prophylaxis of dental caries

    Dosage

    Adults

    Daily use: Dilute 5 drops in 10 ml of water of the 2% mouthwash or use 5 to 10 ml undiluted of the 0.05% mouthwash.

    Weekly use: Dilute 20 drops in 10 ml of water of the 2% mouthwash.

    Elderly

    Daily use: Dilute 5 drops in 10 ml of water of the 2% mouthwash or use 5 to 10 ml undiluted of the 0.05% mouthwash.

    Weekly use: Dilute 20 drops in 10 ml of water of the 2% mouthwash.

    Children

    Children over 8 years
    Daily use: Dilute 5 drops in 10 ml of water of the 2% mouthwash or use 5 to 10 ml undiluted of the 0.05% mouthwash.

    Weekly use: Dilute 20 drops in 10 ml of water of the 2% mouthwash.

    Children over 6 years
    Daily use: 5 to 10 ml undiluted of the 0.05% mouthwash.

    Administration

    Rinse teeth thoroughly for one minute and then spit out.

    Do not eat, drink or rinse mouth for at least fifteen minutes afterwards.

    Contraindications

    Children under 6 years

    Precautions and Warnings

    Children aged 6 to 8 years
    Hereditary fructose intolerance

    Not all available brands are licensed for all age groups
    May contain sodium benzoate: mild mucous membrane irritant
    Presentations with sorbitol unsuitable in hereditary fructose intolerance
    Some formulations may contain alcohol
    Advise patient not to exceed stated dose
    Advise patient not to swallow

    Pregnancy and Lactation

    Pregnancy

    This product is considered safe for use in pregnancy.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Lactation

    This product is considered safe for use in breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1

    Side Effects

    None Known

    Overdosage

    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

    Further Information

    Last Full Review Date: November 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary(online) London: BMJ Group and Pharmaceutical Press [Accessed on 13.11.14].

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications [Accessed on 13.11.14].

    Summary of Product Characteristics: Endekay Fluorinse 2% Mouthrinse. Manx Pharma Ltd. October 2014.

    Summary of Product Characteristics: Endekay Daily Fluoride Mouthrinse. Manx Pharma Ltd. October 2014.

    Summary of Product Characteristics: Fluorigard Daily Rinse 0.05% Dental Solution. Colgate-Palmolive (UK) Ltd. February 2013.

    Summary of Product Characteristics: Fluorigard Alcohol Free Mouth Rinse. Colgate-Palmolive (UK) Ltd.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.